Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EIK 1003 (Primary)
  • Indications Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Eikon Therapeutics

Most Recent Events

  • 29 May 2025 According to an Eikon Therapeutics media release, data from this study presented at the 2025 American Association for Cancer Research (AACR) conference.
  • 29 May 2025 According to an Eikon Therapeutics media release, initial pharmacokinetic, safety, tolerability, and early efficacy findings from the monotherapy dose-escalation cohort will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 - June 3, 2025, in Chicago, Illinois.
  • 30 Apr 2025 Trial design presented at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top